Formulary
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
| 12 SQ-HDM SLIT for ALLERGIC RHINITIS caused by house dust mites Acarizax® |
|
Formulary
|
Red RAG rating to be reviewed in May 2026
Important safety informationFor house dust mite extract:
Desensitising vaccines
In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for licensed indications.
Desensitising vaccines should generally be avoided or used with particular care in patients with asthma. |
 NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites |
|
| Benralizumab Fasenra® |
|
Formulary
|
(Fasenra®) Solution for injection pre-filled syringes 30mg/1ml and solution for injection pre-filled pen 30mg /1ml Severe eosinophilic asthma in adults (add-on therapy) - NICE TA565 Treatment of relapsing or refractory eosinophilic granulomatosis with polyangiitis NICE TA1096 |
|
NICE TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis NICE TA565: Benralizumab for treating severe eosinophilic asthma |
|
| Betula verrucosa Itulazax 12 SQ Bet |
|
Formulary
|
Red RAG rating to be reviewed in May 2026
For treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen.
Desensitising vaccines
In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for licensed indications.
Desensitising vaccines should generally be avoided or used with particular care in patients with asthma. |
|
NICE TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen |
|
|
| Mepolizumab |
|
Formulary
|
(Nucala®) solution for injection pre-filled syringe 40mg / 0.4ml, 100mg powder for solution for injection, solution for injection pre-filled pen 100mg / 1ml, solution for injection in pre-filled syringe 100mg / 1ml Severe eosinophilic asthma in adults - NICE TA671 |
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
|
|
| Palforzia |
|
Formulary
|
Oral powder in capsules for opening 0.5mg, 1mg, 10mg, 20mg, 100mg, 300mg peanut protein as defatted powder of Arachis hypogaea L., semen (peanuts) In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for licensed indications. Self-injectable adrenaline must be prescribed to patients receiving this medicinal product. |
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
|
|
| Reslizumab |
|
Formulary
|
(Cinqaero®) concentrate for solution for infusion 25mg/2.5ml, 100mg/10ml Severe eosinophilic asthma as per NICE TA479 |
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
|
|
| 12 SQ-HDM SLIT for ALLERGIC ASTHMA caused by house dust mites Acarizax® |
|
Formulary
|
|
NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites |
|
| Mepolizumab |
|
Formulary
|
Eosinophilic granulomatosis with polyangiitis in people 6 years and over. Appraisal terminated NICE TA845 |
|
|
| Mepolizumab |
|
Formulary
|
Severe chronic rhinosinusitis with nasal polyps in adults. Appraisal terminated. NICE TA847 |
|
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- Biosimilars policy statement
- BNF: Antihistamines, allergen immunotherapy and allergic emergencies
- LSCMMG: Asthma Treatment Guideline for Adults (aged 12 and over)
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: COPD Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
- NICE TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
- NICE TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
- NICE TA1096: Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
- NICE TA278: Omalizumab for treating severe persistent allergic asthma
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA479: Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA671: Mepolizumab for treating severe eosinophilic asthma
- NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
- NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation
- NICE TA769: Palforzia for treating peanut allergy in children and young people
- NICE TA880 Tezepelumab for treating severe asthma